Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins

Article

Merck Serono (Geneva, Switzerland), a division of Merck KGaA, will collaborate with Flamel Technologies (Lyon, France) to investigate the applicability of Flamel’s Medusa technology for the extended release of a therapeutic protein in Merck Serono’s portfolio.

Merck Serono (Geneva, Switzerland), a division of Merck KGaA, will collaborate with Flamel Technologies (Lyon, France) to investigate the applicability of Flamel’s Medusa technology for the extended release of a therapeutic protein in Merck Serono’s portfolio. Under the terms of the agreement, Merck Serono will make an upfront payment of €2 million to Flamel for investigating the therapeutic protein and Merck Serono will fund research and development efforts to be performed at Flamel.

Merck Serono release

Recent Videos
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.